EBMT-EHA CAR-T 2019 | EBMT CAR T-cell priorities
Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA) Nicolaus Kröger, MD University Medical Center Hamburg, Hamburg, Germany, discusses the importance of education for nurses and physicians, the quality assurance system and the use of the data registry for CAR T-cell therapy.
Transcript (edited for clarity):
There are different initiatives. So first of all we want to improve education. And this is the reason why at this meeting you can see, we have specific sessions for data manager. Because these are at last the people who should monitor all these patients, who should report the patient to the registry. And we have dedicated sessions for the nurses, because the nurses have to be trained, because of the side effects. And we have dedicated sessions to the physician. So education is one of our main goal.
And we will start it with an e-learning platform, and we will do something together with EHA. And the second is that we try to improve the quality, the quality system. You may know that for the transplant we have the so-called JC Accreditation. And this is the same in fact in the U.S. And we are trying now to implement this also for immune effector cells, which would include the CAR T-cells, to give also a sense of possibility to get accreditation just for the CAR T-cells if they don’t do the transplant.
And the third important question is actually the registry, which we already discussed. The registry, we are willing to include all the stakeholders to participate in this registry to get this real-world data, real life world data for the patient who receive the CAR T-cells within the next years in Europe.
Get great new content delivered to your inboxSign up